NASH Drug Development Questions? US FDA Has Many Of The Answers

 
• By Brenda Sandburg

From biomarkers to treatment effect size, agency officials respond to some of more than a hundred questions that poured in during a webinar on development of drugs to treat the liver disease.

Liver
FDA officials address questions about development of drugs for NASH liver disease • Source: Shutterstock

More from US FDA

More from Agency Leadership